Effects of parathyroid hormone 1-34 on osteogenic and chondrogenic differentiation of human fracture haematoma-derived cells in vitro

被引:2
|
作者
Dogaki, Yoshihiro [1 ]
Lee, Sang Yang [1 ]
Niikura, Takahiro [1 ]
Koga, Takaaki [1 ]
Okumachi, Etsuko [1 ]
Nishida, Kotaro [1 ]
Kuroda, Ryosuke [1 ]
Kurosaka, Masahiro [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Orthopaed Surg, Kobe, Hyogo, Japan
基金
日本学术振兴会;
关键词
parathyroid hormone; osteogenic differentiation; chondrogenic differentiation; fracture haematoma; fracture healing; PROGENITOR CELLS; TERMINAL DIFFERENTIATION; POSTMENOPAUSAL WOMEN; HEALING PROCESS; BONE-MARROW; OSTEOBLAST; PROLIFERATION; INTERMITTENT; PTH; CHONDROCYTES;
D O I
10.1002/term.1818
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Parathyroid hormone (PTH) 1-34 has been shown to accelerate fracture healing. Previously, we reported that progenitor cells with osteogenic and chondrogenic potential exist in human fracture haematoma, suggesting that the fracture haematoma-derived progenitor cells (HCs) contribute to fracture healing. However, there has been no study investigating the effect of PTH on HCs. We investigated the effect of pulsatile and continuous PTH treatment on human fracture HCs in vitro. HCs were isolated from seven patients. The HCs were divided into four groups: growth medium; control [ osteogenic medium (OM) without PTH]; PTH-C (OM with continuous PTH); and PTH-P (OM with pulsatile PTH) groups. Osteogenic differentiation potential and proliferation of HCs were compared among the four groups. For chondrogenesis, the HCs were divided into two groups: control [ chondrogenic medium (CM) without PTH]; and PTH-C (CM with continuous PTH) groups, and chondrogenic differentiation potential was analysed. PTH treatment did not affect cell proliferation, regardless of the mode of administration. Osteogenic activity was also not significantly affected by continuous PTH treatment but significantly inhibited by pulsatile PTH treatment. Conversely, chondrogenic differentiation was significantly inhibited by continuous PTH treatment. Our results revealed that PTH treatment on HCs, either continuous or pulsatile, does not exhibit any positive effect, and indicates that exogenous PTH administration after fracture has no effect on HCs. PTH may not have a positive effect at the fracture site during the early stage of fracture healing in which haematoma formation occurs. Copyright (C) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:E365 / E371
页数:7
相关论文
共 50 条
  • [22] 1-34 HUMAN PARATHYROID-HORMONE RADIOIMMUNOASSAY - PROPERTIES OF ANTISERUM AGAINST SYNTHETIC 1-34 HUMAN PARATHYROID-HORMONE AND ITS CLINICAL-APPLICATION
    SHIRAKI, M
    KAWADA, N
    AKIGUCHI, I
    YAMAUCHI, H
    KOJIMA, A
    ORIMO, H
    [J]. ENDOCRINOLOGIA JAPONICA, 1981, 28 (02): : 239 - 244
  • [23] Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure
    Frolik, CA
    Black, EC
    Cain, RL
    Satterwhite, JH
    Brown-Augsburger, PL
    Sato, M
    Hock, JM
    [J]. BONE, 2003, 33 (03) : 372 - 379
  • [24] STRUCTURE OF HUMAN PARATHYROID HORMONE(1-34) IN THE PRESENCE OF SOLVENTS AND MICELLES
    STRICKLAND, LA
    BOZZATO, RP
    KRONIS, KA
    [J]. BIOCHEMISTRY, 1993, 32 (23) : 6050 - 6057
  • [25] SYNTHETIC HUMAN PARATHYROID HORMONE-(1-34) FOR THE STUDY OF PSEUDOHYPOPARATHYROIDISM
    MALLETTE, LE
    KIRKLAND, JL
    GAGEL, RF
    LAW, WM
    HEATH, H
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (05): : 964 - 972
  • [26] Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34)
    Suzuki, Y
    Iga, K
    Yanai, S
    Matsumoto, Y
    Kawase, M
    Fukuda, T
    Adachi, H
    Higo, N
    Ogawa, Y
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (09) : 1227 - 1234
  • [27] Teriparatide [human parathyroid hormone (1-34)] therapy in men with osteoporosis
    Kaufman, J. -M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S184 - S185
  • [28] Electronically facilitated transdermal delivery of human parathyroid hormone (1-34)
    Medi, BA
    Singh, J
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 263 (1-2) : 25 - 33
  • [29] A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis
    Feng, Jiao
    Liu, Yanhua
    Xing, Yun
    Wang, Huaqian
    Li, Taiming
    Liu, Jingjing
    Fan, Hao
    Cao, Rongyue
    [J]. PEPTIDES, 2009, 30 (06) : 1173 - 1180
  • [30] Parathyroid hormone 1-34 reduces dexamethasone-induced terminal differentiation in human articular chondrocytes
    Chang, Ling-hua
    Wu, Shun-Cheng
    Chen, Chung-Hwan
    Wang, Gwo-Jaw
    Chang, Je-Ken
    Ho, Mei-Ling
    [J]. TOXICOLOGY, 2016, 368 : 116 - 128